Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 08 - 05 tags : Cancer save search
Lung Cancer Drug Candidate Offers Patients Hope for Longer Life
Published: 2021-08-05 (Crawled : 17:00) - biospace.com/
SNY | News | $47.1 -1.24% 260K
|
Health Technology
|
| O: 1.14%
H: 0.3%
C: 0.22%
lung cancer cancer drug
Insights on the Kidney Cancer Diagnostics and Therapeutics Global Market to 2026 - Key Motivators, Restraints and Opportunities
Published: 2021-08-05 (Crawled : 16:00) - prnewswire.com
PFE | News 4 | $26.21 -0.42% 5M
|
Health Technology
|
| O: -0.42%
H: 0.31%
C: 0.13%
NVS | News | $98.03 0.77% 650K
|
Health Technology
|
| O: 0.48%
H: 0.24%
C: 0.24%
GSK | News | $40.82 -1.02% 230K
|
Health Technology
|
| O: 0.69%
H: 0.37%
C: 0.34%
SNY | News | $47.1 -1.24% 260K
|
Health Technology
|
| O: 1.14%
H: 0.3%
C: 0.22%
EXEL | $23.55 1.12% 160K
|
Health Technology
|
| O: 0.0%
H: 2.03%
C: 1.25%
AZN | News | $70.905 0.08% 1.6M
|
Health Technology
|
| O: 1.48%
H: 0.46%
C: 0.43%
ADAP | $1.09 -4.39% 200K
|
Health Technology
|
| O: 0.58%
H: 4.05%
C: 2.02%
cancer diagnostics kidney diagnostic
Global Cancer Therapies Market to Reach $204.2 Billion by 2024
Published: 2021-08-05 (Crawled : 15:15) - prnewswire.com
TAK | News | $13.26 -0.9% 210K
|
Health Technology
|
| O: 0.0%
H: 0.61%
C: 0.55%
PFE | News 4 | $26.21 -0.42% 5M
|
Health Technology
|
| O: -0.42%
H: 0.31%
C: 0.13%
NVS | News | $98.03 0.77% 650K
|
Health Technology
|
| O: 0.48%
H: 0.24%
C: 0.24%
JNJ | News | $147.885 -1.12% 1.5M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: -0.09%
GSK | News | $40.82 -1.02% 230K
|
Health Technology
|
| O: 0.69%
H: 0.37%
C: 0.34%
LLY | News | $733.27 -1.67% 470K
|
Health Technology
|
| O: 0.31%
H: 0.85%
C: 0.35%
BMY | $48.64 -0.71% 2.3M
|
Health Technology
|
| O: 0.26%
H: 0.13%
C: -0.36%
AZN | News | $70.905 0.08% 1.6M
|
Health Technology
|
| O: 1.48%
H: 0.46%
C: 0.43%
cancer therapy
Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published: 2021-08-05 (Crawled : 13:00) - biospace.com/
TAK | News | $13.26 -0.9% 210K
|
Health Technology
|
| O: 0.0%
H: 0.61%
C: 0.55%
EXEL | $23.55 1.12% 160K
|
Health Technology
|
| O: 0.0%
H: 2.03%
C: 1.25%
new drug fda cancer drug fda acceptance
Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer
Published: 2021-08-05 (Crawled : 13:00) - biospace.com/
GILD | $66.85 -0.27% 1M
|
Health Technology
|
| O: 0.0%
H: 0.13%
C: 0.09%
collaboration cancer research announces collaboration therapy
Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC)
Published: 2021-08-05 (Crawled : 12:00) - globenewswire.com
PRTG | $0.2547 4.99% 41K
|
Mining, Quarrying, and Oil and ...
|
| O: 1.25%
H: 13.6%
C: 12.88%
treatment lung cancer cancer biotech iot
Syros Announces Agreement with Roche to Evaluate SY-5609 as Part of a Novel Combination for Treatment of Colorectal Cancer
Published: 2021-08-05 (Crawled : 12:00) - biospace.com/
SYRS | $5.14 10K
|
Health Technology
|
| O: 2.88%
H: 5.82%
C: 5.6%
treatment cancer colorectal cancer
Phase 3 Trial of Libtayo® (cemiplimab-rwlc) Combined with Chemotherapy Stopped Early Due to Significant Improvement in Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer
Published: 2021-08-05 (Crawled : 11:00) - biospace.com/
SNY | News | $47.1 -1.24% 260K
|
Health Technology
|
| O: 1.14%
H: 0.3%
C: 0.22%
REGN | News | $914.08 0.75% 54K
|
Health Technology
|
| O: 1.32%
H: 2.47%
C: 2.35%
lung cancer therapy cancer phase 3 trial
Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer
Published: 2021-08-05 (Crawled : 11:00) - biospace.com/
SNY | News | $47.1 -1.24% 260K
|
Health Technology
|
| O: 1.14%
H: 0.3%
C: 0.22%
REGN | News | $914.08 0.75% 54K
|
Health Technology
|
| O: 1.32%
H: 2.47%
C: 2.35%
lung cancer therapy cancer phase 3 trial
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
CZOO | $11.44 129.26% 4.6M
|
BOF | $1.93 64.96% 55M
|
AMST | $3.14 57.0% 59M
|
Technology Services
CSSE 4 | $0.23 51.02% 46M
|
Consumer Services
TROO | $1.57 44.04% 2.8M
|
Manufacturing
RILY | $30.87 42.13% 7.8M
|
Finance
LICN | $0.76 35.71% 6.2M
|
WHLM | $6.61 30.12% 400K
|
Commercial Services
MULN | News | $3.53 29.3% 4.8M
|
Information
RBBN 4 | $3.26 26.85% 1.2M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.